• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

byDaniel GoldshteinandSze Wah Samuel Chan
December 28, 2022
in Chronic Disease, Dermatology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab

2. All patients with tumor-infiltrating lymphocytes therapy had grade 3 or higher adverse events, mainly related to chemotherapy-related neutropenia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with metastatic melanoma have various treatment options available such as PD-1 inhibitors, anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4), and BRAF and MEK inhibition, but these do not confer durable benefits to all patients. Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) is an autologous treatment that involves the outgrowth of tumor-resident T cells with interleukin-2 to enhance the expansion of the cells and augment antitumor responses. This is a phase 3 study that explores TILs vs ipilimumab as first or second-line treatment in patients with advanced melanoma. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), complete response (CR), health-related quality of life (HRQoL), and safety. This study found improvement in PFS (7.2 months in the TIL group vs 3.1 months with ipilimumab, HR 0.50), OS (25.8 months in the TIL group vs 18.9 months in the ipilimumab group, HR 0.83 [not significant]), and CR (20% in the TIL group vs 7% in the ipilimumab group). Safety was generally worse in the TIL group as adverse events grade 3 or higher occurred in 100% of patients mainly due to chemotherapy-induced neutropenia, compared to 57% for the ipilimumab group. HRQoL was slightly higher in the TIL group vs the ipilimumab group with regards to global QoL, physical functioning, and emotional functioning. The strengths of this study included capturing a wide variety of outcome measures. The limitations of this study include the small sample size and the non-blinded nature of the treatments. Overall, this study shows that in patients with advanced melanoma, TILs therapy shows promising results when compared to immune-checkpoint blockade and further studies will clarify the role in advanced melanoma treatment.

Click to read the study in NEJM

Relevant Reading: Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

In-Depth [randomized controlled trial]: This is a multicenter, open-label, phase 3 trial with patients who have unresectable or metastatic stage IIIc or IV cutaneous melanoma, that were randomized to receive either TILs (84 patients) or ipilimumab (84 patients). Those assigned to TIL underwent metastasectomy for the retrieval and expansion of TILs, followed by cyclophosphamide and fludarabine, then a single intravenous adoptive transfer of TILs, and subsequent high-dose interleukin-2. The overall median follow-up time was 33 months. PFS was 7.2 months (95%CI, 4.2 to 13.1) in the TIL group vs 3.1 months (95%CI, 3.0 to 4.3) with ipilimumab, HR 0.50 (95%CI, 0.35 to 0.72; P<0.001). Median OS in the TIL group was 25.8 months (95%CI, 18.2 to not reached) vs 18.9 months (95%CI, 13.8 to 32.6) in the ipilimumab group, HR 0.83 (95%CI, 0.54 to 1.27). Complete responses were seen in 20% (95%CI, 12 to 30) in the TIL group and 7% (95%CI, 3 to 15) in the ipilimumab group. Treatment-related adverse events grade 3 or higher occurred in 100% of the TIL group mainly due to chemotherapy-induced neutropenia but other adverse events included CR increase, hypertension, and hypoxia. For the ipilimumab group, treatment-related adverse events grade 3 or higher occurred in 57% of patients. HRQoL was overall higher in the TIL group vs the ipilimumab group, with global QoL mean scores 77.4 vs 69.6, physical functioning 82.0 vs 79.1, and emotional functioning 85.4 vs 75.7. Overall, this paper shows that treatment with TILs is promising compared to treatment with ipilimumab in patients with advanced melanoma.

RELATED REPORTS

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced melanomaipilimumabTumour-infiltrating cells
Previous Post

Double embryo transfer may be associated with neonatal risks

Next Post

Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

RelatedReports

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

March 21, 2023
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

March 15, 2023
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 9, 2023
#VisualAbstract: Adjuvant pembrolizumab improves distant  metastasis-free survival in stage IIB-C melanoma
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

February 13, 2023
Next Post
Time from symptom onset may not predict infarct volume in stroke

Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

Antioxidants, omega-3 lack benefit in age-related macular degeneration

Meta-analysis shows significant decrease in age-related macular degeneration risk with metformin use

Bisphosphonate use and risk of atypical femur fractures

Variations in the use of cemented implants for hip fracture repair in Nova Scotia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
  • Wellness Check: Spirituality
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options